F2G and Shionogi move closer to commercializing novel oral antifungal after pivotal trial results
Shionogi shares gain as olorofim's Phase 3 success advances its F2G partnership. Explore the $480M deal, FDA plans and market potential.
Roivant Sciences targets new uveitis market as brepocitinib delivers major clinical breakthrough
Roivant Sciences stock rises after brepocitinib's double Phase 3 uveitis success. Explore its FDA plans, cash strength and growth potential.
Trump-Musk Starshield dispute eases as Ukraine restores drone connectivity after week of military disruption
Ukraine restores Starshield access after restrictions disrupted drone defenses. Discover what changed and why questions over SpaceX remain.
Trump administration gives California counties 48 hours to verify ballots as election legal battle intensifies
Justice Department demands California verify suspected noncitizen ballots. Explore the legal battle, disputed data and impact on the 2026 midterms.
US pulls diplomats from Middle East as intelligence warns of advanced Iranian attack plots
US reduces Middle East embassy staffing over Iranian attack threats. Discover which countries are affected and why regional tensions are rising.
Odyssey Therapeutics targets major inflammatory bowel disease opportunity with oral OD-001
Odyssey Therapeutics stock rises on OD-001 ulcerative colitis results. Explore its $433M cash position, clinical trials and growth prospects.
BioVie stock tumbles 9% despite promising Parkinson’s drug results as Phase 3 financing concerns loom
BioVie stock falls despite promising bezisterim Parkinson's data. Explore the Phase 3 opportunity, financing risks and investor outlook
RAPP stock gains on RAP-219 clinical success as Wall Street weighs modest treatment benefit
Rapport Therapeutics' RAP-219 trial lifts RAPP stock as investors weigh its bipolar mania potential. Discover the Phase 3 outlook and market risks.
Pharming Group tightens 2026 revenue guidance to $380m–$390m after strong third-quarter sales
Pharming Group Q3 revenue rises 21% to $117.6 million as Joenja sales jump 58%. Explore revised guidance, expenses and investor outlook.
Macron tightens France protest restrictions as nationwide unrest raises fears of another violent weekend
Macron tightens protest restrictions as France braces for renewed unrest. Discover what is driving the demonstrations and the political fallout.